Search

everythinglearnresearchcommunity

for

Search:↓

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Intestinal intraepithelial lymphocytes are crucial for gut immunity and maintaining the mucosal barrier.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

Imiquimod cream activates hair follicle stem cells and causes early hair growth by changing immune cells and certain protein expressions.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

New treatments like JAK inhibitors show promise for reversing alopecia areata.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

JAK inhibitors are effective for long-term management of alopecia areata.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

A cancer patient's hair became permanently curly after treatment with nivolumab.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.